All In Biotech

NDA 021682 · Mission Pharma

Tindamax

Tinidazole · Oral

Orphan

Last checked: Nov 19, 2026Latest source record: May 17, 2004 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

May 17, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

44

9 Phase 3, 2 recruiting

FAERS reports

435

314 serious, 20 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 17, 2004 Original approval · Type 6 - New Indication (no longer used) OrphanReview
2 products under this application
  • TINDAMAX · TINIDAZOLE 500MG · TABLET, ORAL · Prescription
  • TINDAMAX · TINIDAZOLE 250MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tinidazole" as an intervention, any sponsor and status, largest first.

All 44 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective33
  • nausea28
  • off label use26
  • pruritus26
  • headache25
  • diarrhoea22
  • vomiting22
  • pyrexia21
  • rash21
  • anxiety20
  • neuropathy peripheral19
  • paraesthesia19

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20058
20063
20074
20085
200910
201011
201116
201218
201318
201425
201521
201631
201718
201827
201938
202049
202131
202224
202334
202412
202524
20268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 390 on PubMed

Sponsor: Mission Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.